Comparison of PBMT and concomitant quadruple therapy of Helicobacter pylori as a first-line therapy in Korea: prospective randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0001821

Enrollment

132

Registered

2016-02-18

Start date

2016-03-01

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : 1.Helicobacter pylori infection and then determines whether come out positive in at least two or more of the listed ones. (1) Rapid urease test positive (2) Giemsa staining positive (3) Positiv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Infected with Helicobacter 2) Men and women aged 18-70 3) Patients agreed to participate in this study and understand the purpose of the present study 4) The patients who peptic ulcer disease, underwent endoscopic resection for early gastric cancer, MALT lymphoma, and if patient want Helicobacter pylori eradication

Exclusion criteria

Exclusion criteria: 1) Patients treated with H. pylori eradication therapy earlier 2) Patients with other systemic disorder such as severe dysfunction of liver, kidney, heart, and lung 3) Pregnant patients as possible during the study period or during pregnancy 4) Other researchers have been not suitable for the patient determines

Design outcomes

Primary

Measure	Time frame
The eradication rate of Helicobacter pylori	—

Secondary

Measure	Time frame
Compliance and side effects of the drug treatment;Whether resistant strains of Helicobacter pylori	—

Countries

Korea, Republic of

Contacts

Public ContactSu Young Kim

Gachon University Gil Medical Center

breeze1212@naver.com+82-32-460-3778

Outcome results